Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Alx Oncology Holdings (ALXO) Research & Development (2019 - 2026)

Alx Oncology Holdings' Research & Development history spans 5 years, with the latest figure at $41.8 million for Q4 2023.

  • On a quarterly basis, Research & Development rose 65.83% to $41.8 million in Q4 2023 year-over-year; TTM through Dec 2023 was $141.8 million, a 44.1% increase, with the full-year FY2025 number at $77.0 million, down 33.84% from a year prior.
  • Research & Development hit $41.8 million in Q4 2023 for Alx Oncology Holdings, down from $45.8 million in the prior quarter.
  • Over the last five years, Research & Development for ALXO hit a ceiling of $45.8 million in Q3 2023 and a floor of $2.2 million in Q3 2019.
  • Historically, Research & Development has averaged $18.0 million across 5 years, with a median of $17.1 million in 2022.
  • Biggest five-year swings in Research & Development: soared 241.85% in 2021 and later grew 10.22% in 2023.
  • Tracing ALXO's Research & Development over 5 years: stood at $6.7 million in 2019, then skyrocketed by 80.28% to $12.1 million in 2020, then soared by 72.08% to $20.9 million in 2021, then rose by 20.59% to $25.2 million in 2022, then skyrocketed by 65.83% to $41.8 million in 2023.
  • Business Quant data shows Research & Development for ALXO at $41.8 million in Q4 2023, $45.8 million in Q3 2023, and $29.5 million in Q2 2023.